Hello my dears,
I came across the company in an analysis based on Buffet`s Alpha $INCY (-0.3%) company.
I noticed the enormous increase in the margin starting next year, which will lead to a profit growth of 356% and a reduction in the P/E ratio.
Here is my question: Are you from the community here aware of anything that leads to this?
(New drugs etc.)
The company currently has 25 drugs in the pipeline, some of which are already in Phase II trials.
Business model and segments
Incyte's business model is easy to understand. The company conducts research in the fields of myeloproliferative neoplasms (MPNs), graft-versus-host disease (GVHD), hematology, oncology and dermatology as well as other inflammatory and autoimmune diseases. Since its foundation in 2002, Incyte has succeeded in obtaining marketing authorization for seven drugs. These include Jakafi, which is used to treat chronic blood cancer.
Another important drug from Incyte is Opzelura. This is available on prescription and is used on the skin for the short-term and non-continuous treatment of mild to moderate eczema. The market share of Opzelura in new patients who do not respond to steroid treatment is over 12%. Pemazyre is a drug for the treatment of cancer of the biliary tract.
The company is active worldwide. At 72%, the majority of sales are currently generated in the USA. Total sales amounted to USD 2.96 billion in 2021. The largest turnover is generated with Jakafi. While this amounted to USD 1.938 billion in 2020, it soared to USD 2.13 billion in 2021. License revenue for Jakavi, Olumiant and Tabrecta amounted to USD 569 million in 2021.
